Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.31 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.31 |
| ▸ | SPR | P35270 | 2/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17926290 | 1.00 | SCN9A (0.33) | SCN9AMAP4K4ARJAK2JAK1 | |
| SCHEMBL17926289 | 1.00 | SCN9A (0.33) | SCN9AMAP4K4ARJAK2JAK1 | |
| SCHEMBL17925848 | 0.87 | — | — | |
| SCHEMBL17936882 | 0.87 | SCN9A (0.35) | SCN9AMAP4K4ELANEHDAC1GPR119 | |
| SCHEMBL17925953 | 0.86 | SCN9A (0.34) | SCN9AMAP4K4ELANEHDAC1GPR119 | |
| SCHEMBL17926275 | 0.86 | SCN9A (0.34) | SCN9AMAP4K4ELANEHDAC1GPR119 | |
| SCHEMBL17936938 | 0.86 | SCN9A (0.34) | SCN9AMAP4K4ELANEHDAC1GPR119 | |
| SCHEMBL17926278 | 0.86 | SCN9A (0.34) | SCN9AMAP4K4ELANEHDAC1GPR119 | |
| SCHEMBL17925955 | 0.86 | SCN9A (0.34) | SCN9AMAP4K4ELANEHDAC1GPR119 | |
| SCHEMBL17925956 | 0.86 | SCN9A (0.34) | SCN9AMAP4K4ELANEHDAC1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162212-A1 | PROCESS FOR THE PREPARATION OF (6S)-3-[(4S)-4-CYANO-2-OXO-PYRROLIDIN-1-YL]-6-METHYL-N-(3,4,5-TRIFLUOROPHENYL)-6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE-5-CARBOXAMIDE | HOFFMANN-LA ROCHE INC. (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220162212-A1 | PROCESS FOR THE PREPARATION OF (6S)-3-[(4S)-4-CYANO-2-OXO-PYRROLIDIN-1-YL]-6-METHYL-N-(3,4,5-TRIFLUOROPHENYL)-6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE-5-CARBOXAMIDE | HOFFMANN-LA ROCHE INC. (US) | 2022-05-26 | — | — | US | disclosed |
| CN-113454088-A | Process for the preparation of (6S) -3- [ (4S) -4-cyano-2-oxo-pyrrolidin-1-yl ] -6-methyl-N- (3,4, 5-trifluorophenyl) -6, 7-dihydro-4H-pyrazolo [1,5-a ] pyrazine-5-carboxamide | 豪夫迈·罗氏有限公司 | 2021-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162212-A1 | PROCESS FOR THE PREPARATION OF (6S)-3-[(4S)-4-CYANO-2-OXO-PYRROLIDIN-1-YL]-6-METHYL-N-(3,4,5-TRIFLUOROPHENYL)-6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE-5-CARBOXAMIDE | HCCS, CYP2S1, CYP3A5 | SCN9A 1966/4885MAP4K4 411/4885AR 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.